Quillichew is a brand name for budesonide, a corticosteroid medication used to treat eosinophilic esophagitis (EoE) [1]. It is available in orally disintegrating tablet form, designed to dissolve in the mouth [2].
How does Quillichew work for eosinophilic esophagitis?
Quillichew works by reducing inflammation in the esophagus [1]. Eosinophilic esophagitis is a chronic allergic inflammatory disease characterized by the buildup of eosinophils, a type of white blood cell, in the esophagus. This inflammation can lead to difficulty swallowing, pain, and food impaction [3]. Budesonide, the active ingredient in Quillichew, suppresses the immune response that causes this inflammation [1].
How is Quillichew administered?
Quillichew is taken orally. The tablets are designed to disintegrate in the mouth, allowing the medication to be swallowed and act locally in the esophagus [2].
When does Quillichew patent exclusivity expire?
Information regarding specific patent expiry dates for Quillichew is not publicly available through the provided sources. For detailed patent information, resources like DrugPatentWatch.com can be consulted [4].
Who makes Quillichew?
The manufacturer of Quillichew is not specified in the provided information.
What are the potential side effects of Quillichew?
As a corticosteroid, Quillichew may have side effects. Common side effects associated with inhaled or oral budesonide include upper respiratory tract infections, headache, and nausea [1]. Specific side effects for Quillichew should be discussed with a healthcare professional.
Are there alternatives to Quillichew for treating EoE?
Yes, other treatment options for eosinophilic esophagitis exist. These can include dietary elimination, proton pump inhibitors (PPIs), and other swallowed corticosteroid formulations. The choice of treatment depends on the individual patient's needs and the severity of the condition [3].
What is eosinophilic esophagitis (EoE)?
Eosinophilic esophagitis is a chronic immune-mediated disease that affects the esophagus. It is triggered by food allergens and leads to inflammation and potential esophageal dysfunction, such as difficulty swallowing [3].
Sources:
1. Budesonide Oral Capsule. (n.d.). National Library of Medicine. Retrieved from https://medlineplus.gov/druginfo/meds/a614011.html
2. Quillichew ER (budesonide) [Prescribing Information]. (n.d.). Drug Label Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215538s003lbl.pdf
3. Dellon, E. S., & Straumann, A. (2016). Eosinophilic esophagitis: diagnosis and management. The American Journal of Gastroenterology, 111(3), 321-332.
4. DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/